Fig. 3: LRIG2 inhibits cell-cycle progression in endometrial carcinoma, and this is mediated by p21. | Oncogenesis

Fig. 3: LRIG2 inhibits cell-cycle progression in endometrial carcinoma, and this is mediated by p21.

From: LRIG2 is a growth suppressor of Hec-1A and Ishikawa endometrial adenocarcinoma cells by regulating PI3K/AKT- and EGFR-mediated apoptosis and cell-cycle

Fig. 3

a LRIG2-induced effects on cell-cycle progression were assessed in LRIG2–GFP-overexpressing or LRIG2-depleted Hec-1A cells. Representative histograms and quantified cell populations in the G0/G1, S, and G2/M phases are shown. b, c The same cells shown in a were used for immunoblotting b or real-time RT-PCR c to detect p21. d Human p21 promoter activation by LRIG2 was determined by luciferase assays 24 h after transfection in Hec-1A cells transfected with increasing amounts of plasmid (50, 100, or 200 ng) encoding LRIG2–GFP. e Hec-1A cells were transfected with control siRNAs or p21-specific siRNAs for 24 h. Cells were then further transfected with either an empty vector or the LRIG2 plasmid, and cell proliferation was assayed after 24 h. Effective p21 knockdown was confirmed by immunoblotting. All quantified results are mean ± SEM of three independent experiments performed in triplicates (*p < 0.05). Different letters indicate statistically significant values (p < 0.05)

Back to article page